• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Anaptysbio Inc (NQ: ANAB )

    35.71 +2.01 (+5.96%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 327,063
    Open 34.34
    Bid (Size) 35.20 (1)
    Ask (Size) 36.80 (2)
    Prev. Close 33.70
    Today's Range 33.87 - 35.75
    52wk Range 13.36 - 37.28
    Shares Outstanding 27,433,359
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
    HC Wainwright initiated coverage on AnaptysBio with a Buy rating and a $55 price target. AnaptysBio focuses on immunology therapeutics with a promising pipeline. 
    Via Benzinga
    The Analyst Landscape: 7 Takes On AnaptysBio
    Via Benzinga

    Performance

    YTD
    +64.56%
    +64.56%
    1 Month
    +48.79%
    +48.79%
    3 Month
    +81.64%
    +81.64%
    6 Month
    +50.36%
    +50.36%
    1 Year
    +101.87%
    +101.87%

    More News

    Read More
    ANAB Stock Earnings: AnaptysBio Misses EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Unveiling 4 Analyst Insights On AnaptysBio
    Via Benzinga
    Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
    From AnaptysBio, Inc.
    Via GlobeNewswire
    BTIG Research Predicts Over 118% Rally for These 3 Stocks
    Via InvestorPlace
    Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
    Via The Motley Fool
    Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers
    Via Benzinga
    Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys Named a BioSpace 2024 Best Places to Work Winner
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys Announces Participation in November Investor Conferences
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Why Is Skin Disease Focused AnaptysBio Stock Trading Higher Today?
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Argenx's 28% Surge & Promising Product Propel Investor Confidence
    Via MarketBeat
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.